TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05529316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An anti-CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An anti-CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An anti-CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botensilimab
Description: An anti-CTLA-4 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: An anti-PD-1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balstilimab
Description: An anti-PD-1 monoclonal antibody
Study: NCT06533267

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic nasopharyngectomy followed close follow-up
Description: Radical resection of primary lesion using nasal endoscopy.~After the treatment, the electronic nasal endoscopy was reviewed every two weeks to determine the healing of the wound, whether there was tumor recurrence, until the surgical wound was completely healed. The patients were followed up at least once every three months from the first year to the third year, at least once every six months from the fourth year to the fifth year, and at least once every year after five years.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-modulated Radiotherapy
Description: GTVnx (nasopharyngeal lesions): 69.96Gy/33Fr/2.12Gy CTV1: 60.60Gy/33Fr/1.82Gy CTV2: 54.12Gy/33Fr/1.64Gy.~After treatment, patients were followed up every 3-6 months from the first year to the third year, every 6-12 months from the fourth year to the fifth year, and at least once a year after five years.
Study: NCT05433272

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain
Description: The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain
Description: The Trivalent COVID-19 Vaccine (Vero Cell), Inactivated, Prototype Strain, Delta Strain and Omicron Strain was developed by Sinovac Life Science Ltd. The antigen content of trivalent COVID-19 vaccine is a total of 18μg/0.5 ml, including 1200 SU/6 µg/0.5 ml for Prototype strain, 1200 SDU/6 µg/0.5 ml for Delta strain, and 1200 SOU/6 µg/0.5 ml for Omicron strain. The routine of administration is Intramuscular injection into deltoid region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Vaccine (Vero Cell), Inactivated
Description: The COVID-19 Vaccine (Vero Cell),Inactivated was manufactured by Sinovac Life Science Ltd.The antigen content of the active-controlled vaccine (CoronaVac) is 600 SU/3 µg/0.5 ml.The routine of administration is Intramuscular injection into deltoid region.
Study: NCT05519072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: For those randomized to the treatment arm, antibiotics will be prescribed at the discretion of the ordering physician. They will be prescribed only in oral form and in accordance with the patient's allergy profile.
Study: NCT03919344

Intervention type: OTHER
Group type: OTHER
Intervention: Critical airway closure pressure (Pcrit) measurment
Description: Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway

Intervention type: OTHER
Group type: OTHER
Intervention: Critical airway closure pressure (Pcrit) measurment
Description: Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway
Study: NCT04888637

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline MEG Test
Description: Each subject will have one MEG session with the recordings of baseline resting state, language and memory protocols. Subjects will have a break period between the language and memory tasks. MEG recordings will be acquired for approximately 35 minutes. The subject will be allowed to practice the language and memory tasks before the MEG recording to feel familiar with them. This practice phase will be a short version of the task administered by a computer and will take approximately 6 minutes.

Intervention type: BEHAVIORAL
Intervention: Receptive Language Task
Description: The subject will perform a practice session where they will be instructed to try to remember a set of ﬁve audibly spoken English words, deemed targets (jump, little, please, drink, and good). Depending on the subject's overall verbal memory capacity, the target words will be presented once or twice during the practice phase. Subsequently, during the MEG recording, the ﬁve target words will repeat in a different random order, mixed with a different set of 40 distractors (non-repeating words) in each of three blocks of stimuli. The subject's task will be to listen to the words and lift their index finger of the dominant hand whenever they hear a repeated target word (one of the five). After the language task, the subject will be given a break.

Intervention type: BEHAVIORAL
Intervention: Memory Task
Description: The subject will be tasked with indicating whether the encoding stimulus matched the retrieval stimulus using two buttons; one for congruent and the other for incongruent response. Button type will be counterbalanced among subjects. The task will take around 16 minutes. The visual stimuli will be projected through an LCD projector onto a white screen located about 0.5 m in front of the subject and subtending 1.0-4.0 and 0.5 degrees of horizontal and vertical visual angle, respectively. A MEG compatible keyboard will be used to measure the subject's responses for congruent and incongruent. The subject will practice the memory task before going to the MEG system using a computer from MEG laboratory. This practice phase will consist of a short version of the memory task with duration of approximately 4 minutes.
Study: NCT06106815

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises
Description: The Graded Repetitive Arm Supplementary Program (GRASP) is designed to improve upper extremity function in individuals with stroke. The GRASP program includes exercises for stretching, coordination, arm and hand strengthening, and fine motor skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care
Study: NCT05267314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pharyngeal exerciser + standard therapy
Description: Use of Pharyngeal exerciser
Study: NCT05363137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chatbot Assistant
Description: The physiotherpy treatment will be supervised via chatbot

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The physiotherpy treatment will be standard care
Study: NCT06171906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mesenchymal stromal cells
Description: On the basis of conventional PGF treatment for poor implantation, the enrolled patients were injected with 1×10\^6/kg mesenchymal stem cells of cord blood weekly for 4 consecutive weeks
Study: NCT04866511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: NET is a trauma-focused psychological treatment for people who experienced multiple traumas (Schaeur et al., 2011).~An adaptation named KIDNET was developed for use with children and young people (Neuner et al., 2008; Schauer et al., 2011, 2017).~Participants will be offered 6-10 weekly sessions of NET lasting approximately 90 minutes each. The sessions will be delivered by a Trainee Clinical Psychologist via videoconferencing, in line with the UK's Government guidelines around reducing face-to-face contacts during the Covid-19 pandemic.
Study: NCT05723848

Intervention type: DEVICE
Intervention: Smartwatch (Withings Scanwatch)
Description: All-day monitoring of patients via smartwatch
Study: NCT04532242

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal
Description: Participants will be trained to follow instructions to look/respond naturally or use cognitive reappraisal to reframe or reconsider a negative picture to decrease negative emotion.
Study: NCT05468775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Naked eye 3D vision training
Description: 20 minutes of naked eye 3D vision training every day
Study: NCT04466410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Single bolus intrathecal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Single bolus intrathecal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XT-150
Description: Single bolus intrathecal injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a sterile phosphate-buffered saline
Study: NCT05630378

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: outpatient clinic with multimodal integrative medicine and naturopathy for post-COVID-19 patients
Description: Patients receive multimodal integrative medicine and naturopathy applications with focus on mind-body-medicine and whole body hyperthermia to reduce fatigue and improve quality of life.

Intervention type: OTHER
Group type: OTHER
Intervention: waiting group
Description: Patients receive no intervention
Study: NCT05337488

Intervention type: OTHER
Intervention: questionnaire with interview
Description: They will be invited to complete a questionnaire and an individual semi-structured interviews.
Study: NCT05802914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Back Exosuit
Description: The back exosuit is a soft wearable robotic suit designed to improve a wearer physiology, kinetics, kinematics to reduce the possibility of injury. The back exosuit is primarily composed of textiles that wrap around an individual's shoulder (backpack) and thighs (thigh wrap) to serve as anchor points. An actuating element attaches to those anchor elements to provide assistive forces while the user performs a physical activity. The soft wearable robot integrates sensing components to be able to detect user biomechanics and device function and actuating elements via algorithms that command the actuation based on users' intent. To encourage usability, the device is easy to don and intuitive to use. This back exosuit has demonstrated significant reductions in back (18%), hip (11%) and knee (22%) extensor muscle activity during a 1-hour workplace simulation task when compared to lifting without a suit.
Study: NCT05940831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Support-Moms
Description: Scheduled SMS-audio messages from the final messaging prototype (SM), plus social supporter engagement through SMS (SS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine care/ information giving
Study: NCT04584502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Moms Yoga Mindfulness Intervention
Description: MMORE is an 8-session yoga-mindfulness intervention protocol, offered via Zoom over the course of 10 consecutive weeks at the partner maternity care practice or a nearby location. Each session will last approximately 60 minutes (8 - 10 participants per group). Intervention participants will also be asked to use a mobile companion app at least once each week of the intervention period.
Study: NCT06276517

Intervention type: OTHER
Intervention: questionnaire
Description: self-questionnaire with 16 questions, rated from 0 to 4, giving a total of 0 to 52 points.

Intervention type: OTHER
Intervention: SS-QoL
Description: 49-question self-administered questionnaire covering 12 domains (including work/productivity, mood, social roles, family roles, personality, etc.).

Intervention type: OTHER
Intervention: SF-36
Description: multidimensional, generic scale, i.e. one that assesses health status independently of causal pathology, sex, age and treatment

Intervention type: OTHER
Intervention: CIQ-R
Description: 16-question questionnaire with answers rated from 0 to 2 to assess Social reintegration

Intervention type: DIAGNOSTIC_TEST
Intervention: BREFF
Description: rapid frontal efficiency battery, 6 tests from 0 to 3 on each side

Intervention type: DIAGNOSTIC_TEST
Intervention: MoCA
Description: MoCA is a screening test for neurocognitive impairment. It comprises 11 categories scored from 0 to 6 for a total of 0 to 30 points.

Intervention type: OTHER
Intervention: IADL
Description: 8 questions rated from 0 to 1 to assess functional outcome

Intervention type: OTHER
Intervention: mMRS
Description: mMRS score from 0 to 4 to assess functional outcome

Intervention type: OTHER
Intervention: PCL-5
Description: To assess the prevalence of post-traumatic stress using the PCL-5 self-questionnaire. PCL-5 is a 20-item self-administered questionnaire.

Intervention type: OTHER
Intervention: Brief-Cope
Description: 28-question self-questionnaires to study patients' coping strategies
Study: NCT03919344

Intervention type: OTHER
Group type: OTHER
Intervention: Critical airway closure pressure (Pcrit) measurment
Description: Pcrit is measured in awake patient, by applying a gradually decreasing pressure through a nasal NIV mask. Pcrit is defined as the pressure inducing airflow cessation in upper airway

Intervention type: OTHER
Group type: OTHER
Intervention: Acoustic pharyngometry
Description: Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.

Intervention type: OTHER
Group type: OTHER
Intervention: Acoustic pharyngometry
Description: Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.

Intervention type: OTHER
Group type: OTHER
Intervention: Acoustic pharyngometry
Description: Acoustic pharyngometry will assess the volume of the pharynx and determine if there is an obstacle in the upper airways.

Intervention type: OTHER
Group type: OTHER
Intervention: High density surface electroencephalogram neural mapping
Description: Mapping of the respiratory neural network will allow us to study the areas of the brain activated during breathing
Study: NCT05857332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG1906
Description: Phase 1a will use an accelerated titration-Bayesian optimal interval (AT-BOIN) design with 7 dose cohorts: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 6 mg/kg, 9 mg/kg, and 12 mg/kg by IV infusion. Accelerated titration (i.e., 1 patient each) will be applied to the first 2 cohorts.
Study: NCT04764383

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Histidine
Description: 1000 mg capsules taken by mouth (PO) twice daily (BID).
Study: NCT05850182

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 12-week lifestyle intervention including adherence to a personalized balanced dietary regimen (low total fat, low saturated fat, high ω3 fatty acids, optimized protein content, low simple sugars) combined with regular physical activity (including physiotherapy sessions and self-training).
Study: NCT05957809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured exercise training
Description: This group will receive structured exercise training with 60-75 minute sessions per day, 2 days a week, for 8 weeks. • Warm-up program - 10 minutes~* Strength training on unstable surfaces - 25-30 minutes~* High repetition muscular endurance training - 25-30 minutes~* Cool-down program - 10 minutes
Study: NCT05781009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnenolone
Description: 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT05226039

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate intensity acute exercise bout
Description: The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Moderate intensity acute exercise bout
Description: The treatment/intervention will consist of 20 minutes of moderate intensity aerobic exercise on a stationary bike. Intensity will be prescribed based off of heart rate reserve.
Study: NCT05087836

Intervention type: DEVICE
Intervention: Sensor at forehead area
Description: NIRS sensor attached at forehead area.

Intervention type: DEVICE
Intervention: Sensor at temporal area
Description: NIRS sensor attached at temporal area.
Study: NCT04302051

Intervention type: DIAGNOSTIC_TEST
Intervention: Thermo-acuostic image acquisition of liver
Description: Estimation of hepatic fat content with thermo-acoustic device

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI-PDFF estimation of hepatic fat
Description: Estimation of hepatic fat content with MRI
Study: NCT05624489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engagement Strategies
Description: The study's mobile app (Oralytics) will be used to deliver engagement prompts. The prompts contain messages that leverage three engagement strategies: reciprocity, reciprocity by proxy, and curiosity.
Study: NCT06480331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided fistuloplasty
Description: Radiation free fistuloplasty

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-guided fistuloplasty
Description: Conventional fistuloplasty
Study: NCT05264142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole 200mg
Description: Voriconazole is a weak CYP2C19 inhibitor. It is used in study session 2 to study the impact of a weak inhibitor on the phenotype switch among the different genotypes included in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluvoxaMINE 50 Mg Oral Tablet
Description: Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluvoxaMINE 50 Mg Oral Tablet
Description: Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FluvoxaMINE 50 Mg Oral Tablet
Description: Fluvoxamine is a strong CYP2C19 inhibitor. It is used in study session 3 to study the impact of a strong inhibitor on the phenotype switch among the different genotypes included in the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 MG Oral Tablet
Description: Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 MG Oral Tablet
Description: Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 10 MG Oral Tablet
Description: Omeprazole is a CYP2C19 probe substrate. It is used in the study as a tool for CYP2C19 phenotyping at each of the sessions.
Study: NCT05982080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP002 Injection
Description: Up to 6 FP002 dose levels (0.3, 1.0, 3.0, 10, 20, 30 mg/kg administered intravenously may be evaluated. Subjects will receive weekly infusions of FP002 until disease progression, unacceptable toxicity, consent withdrawal, physician decision, or start of subsequent anticancer therapy, whichever occurs first.
Study: NCT05771597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Biofeedback therapy
Description: Patients will be given home biofeedback device to take home and practice biofeedback exercises at least twice a day for six weeks of therapy.~1. HBT for patients with constipation and dyssynergic defecation:~   Patients will attend one session of training on how to use the device followed by daily sessions at home for 6 weeks. After placing a probe into rectum, the patient sits on a commode, activates the smart phone app and follow the voice-guided instructions to perform diaphragmatic breathing exercises and push maneuvers with/without balloon distension.~2. HBT for patients with FI:~   Subject will receive training on how to use the home-trainer device and probe placement. The patient will be asked to follow a series of voice guided instructions consisting of performing short and long duration squeeze maneuvers over 25 minutes.~3. HBT for patients with UI:~The instructions protocol as written above for patients with FI will be followed for UI patients as well.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Office biofeedback therapy
Description: Patients will receive traditional office biofeedback, once weekly, over six weeks.~1. OBT for patients with constipation and dyssynergic defecation:~   The patient will receive instructions on the diaphragmatic breathing techniques. Then the patient sits on a commode, coordination between push effort and the anal and pelvic floor relaxation is corrected by the therapist. The patients will receive visual and verbal feedback instructions from the therapist.~2. OBT for patients with FI:~   Patients will be taught Kegels and abdominal muscle exercises. Visual and verbal feedback techniques are used to reinforce the maneuvers. The patient is instructed to squeeze and to maintain this squeeze for as long as possible.~3. OBT for patients with UI:~Biofeedback training is performed using the protocol and objectives as described above for FI training.